Lakeway, TX — January 5, 2025 — Vigilant Biosciences, a leading innovator and developer of solutions that assist in the early detection of oral cancer, is excited to announce its partnership with AMP as a distributor of its products in the United Kingdom. This collaboration aims to expand access to Vigilant’s groundbreaking diagnostic solutions within the medical community.
As a trusted leader in the medical field, AMP brings a wealth of experience and an established network throughout the UK. This partnership will enhance Vigilant Biosciences’ ability to deliver its innovative cancer-detection technologies to healthcare providers, thereby improving patient outcomes through early intervention.
“We are thrilled to partner with AMP,” said Bill Brodie, CEO at Vigilant Biosciences. “Their expertise and commitment to excellence in the medical industry align perfectly with our mission to provide effective cancer detection solutions. Together, we will empower healthcare professionals with the tools they need to improve patient care.”
Vigilant’s advanced diagnostic technology focuses on early detection of oral cancer, enabling timely intervention and improved patient outcomes. The collaboration with AMP will facilitate the distribution of these vital tools, ensuring that more practitioners can integrate Vigilant’s solutions into their practices.
“In 30 years of clinical dentistry, few innovations have meaningfully strengthened early oral cancer screening. Vigilant’s OraFusion System does exactly that by complementing visual examination with objective salivary biomarker data,” said Professor Bob Khanna, President of IAAFA.
The partnership officially launched in November, with plans for joint training sessions and promotional activities to introduce Vigilant’s products to healthcare professionals across the UK.
For more information about Vigilant Biosciences and its partnership with Aesthetic Medical Partnership, please visit vigilantbiosciences.com or amp-uk.co.uk.
About Vigilant Biosciences
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral cancer. Vigilant’s BeVigilant™ product line includes point-of-care testing that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention.
About AMP
AMP provides regenerative medical technologies that help aesthetic and wellness clinics deliver consistent, high-quality treatment outcomes to the UK and Ireland. AMP offers a portfolio of devices and biologics supported by comprehensive training, marketing, and service. This enables clinics to introduce in-demand treatments with confidence and cost-effective access, through a collaborative approach. AMP works alongside providers to strengthen patient loyalty and support sustainable business growth.
EN 
IT 
DE 
TR 
PT 
NL 
FR 
ES